JS006 is a humanized IgG4kappa monoclonal antibody inhibitor targeting TIGIT/CD155. It is applicable in the study of advanced and/or metastatic cancers, such as non-small cell lung cancer (NSCLC), advanced lymphoma, and advanced/metastatic triple-negative breast cancer (TNBC), particularly when resistance to PD-1/PD-L1 inhibitors has developed.
Target-Kategorie:
Others
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
